Report Highlights

India Transthyretin Amyloidosis: Competitive Overview

The Indian ATTR market is moderately concentrated with two dominant multinational players — Pfizer (tafamidis, Vyndaqel) and Alnylam Pharmaceuticals (patisiran, onpattro; vutrisiran, amvuttra) — collectively commanding over 70% of the treated patient revenue base. Domestic pharmaceutical companies including Sun Pharma and Cipla have not yet entered the branded ATTR therapeutic space, though several are evaluating biosimilar and generic pathways as key patents approach expiration. Competitive advantage in this market is determined primarily by physician education reach, diagnostic partnerships with major tertiary hospitals, and the ability to navigate India's complex reimbursement architecture spanning state government schemes and private insurance panels.

International players benefit from first-mover advantage in building relationships with neurologists and cardiologists at AIIMS Delhi, Apollo Hospitals, and Fortis networks, where most ATTR patients are identified and managed. The competitive moat is reinforced through patient support programs and genetic counseling services that domestic challengers cannot easily replicate without significant capital investment. Ionis Pharmaceuticals, with its eplontersen pipeline, and Intellia Therapeutics, advancing CRISPR-based NTLA-2001, are positioning for late-2020s entry into India, which will fundamentally restructure the competitive hierarchy as treatment paradigms shift from chronic stabilizers to potential one-time curative interventions.

Demand Drivers Shaping Transthyretin Amyloidosis in India

Three demand drivers are reshaping the competitive landscape for ATTR therapeutics in India. First, India's expanding cardiac amyloidosis diagnostic infrastructure — driven by increased availability of technetium pyrophosphate scintigraphy at tier-1 hospitals — is converting historically undiagnosed heart failure cases into confirmed ATTR-CM diagnoses. This trend disproportionately benefits Pfizer, whose tafamidis therapy is specifically indicated for cardiomyopathy and is already positioned within cardiology departments at major private hospital chains. The growing cardiac imaging capacity at centers like Manipal Hospitals and Medanta gives Pfizer a structural channel advantage that RNA-based therapies targeting polyneuropathy have not yet matched.

Second, India's aging population — with over 140 million citizens above age 60 — increases the prevalence pool for wild-type ATTR cardiomyopathy, the most common ATTR subtype globally and one historically overlooked in South Asian populations. Third, government initiatives under the National Programme for Non-Communicable Diseases are improving awareness at district hospital levels, indirectly feeding patient referrals upward to specialist centers where ATTR drugs are prescribed. Alnylam benefits most from this third driver, as its RNA interference therapies are positioned strongly in hereditary ATTR polyneuropathy, which features earlier-onset presentation among the genetically predisposed populations concentrated in South India's high-referral corridors.

Competitive Restraints and Market Challenges

The most acute competitive challenge in India's ATTR market is drug pricing versus affordability. Tafamidis is priced between INR 8–12 lakh annually per patient in private channels, placing it entirely beyond the reach of the estimated 85% of ATTR patients who lack comprehensive insurance coverage. The National Pharmaceutical Pricing Authority has signaled increasing scrutiny of rare disease drug pricing following the 2022 National Policy for Rare Diseases, which introduced a one-time treatment cost support mechanism that is insufficient for chronic therapies. This pricing ceiling compresses revenue potential for all multinational players and creates a persistent out-of-pocket cost barrier that blunts market expansion despite rising diagnostic capability at tertiary centers in metros like Hyderabad and Bengaluru.

Talent availability and diagnostic expertise represent a secondary but significant competitive restraint. India has fewer than 400 neurologists with direct ATTR expertise across the entire country, and the cardiology community's familiarity with ATTR-CM diagnosis remains inconsistent outside top-tier private hospitals. This creates a bottleneck where competitive differentiation at the pharmaceutical level is subordinated to whether a diagnosing physician can identify the condition at all. Companies investing in continuing medical education programs for cardiologists — Pfizer has the most active program currently — gain a structural sales pipeline advantage, while newer entrants face a steep physician education cost that extends their effective market entry timelines by 18 to 24 months.

Growth Opportunities for Market Players

The single largest untapped opportunity in India's ATTR market is the hereditary ATTR polyneuropathy patient population in South India, particularly Tamil Nadu, where the Val30Met mutation prevalence is documented but the diagnosed-to-treated ratio remains critically low. Alnylam and Ionis both have differentiated assets targeting this patient population, and the company that builds an end-to-end genetic testing and patient support infrastructure in Tamil Nadu's tertiary hospital network first will capture a durable patient registry that sustains revenue through the forecast period. This opportunity is not theoretical — it is executable now, and the diagnostic infrastructure at institutions like CMC Vellore is already capable of supporting large-scale TTR genotyping programs.

A second distinct opportunity lies in partnering with India's government-backed rare disease funding mechanisms. The Rashtriya Arogya Nidhi scheme and state-level rare disease funds represent an emerging reimbursement channel that currently covers fewer than 30 ATTR patients annually but is administratively expandable. Multinational players willing to negotiate differential pricing for government reimbursed channels — as Roche has done in oncology and as Sanofi has done for Gaucher disease — can unlock volume growth that partially compensates for compressed private market margins. This government channel strategy also creates a regulatory goodwill buffer that protects against future price control orders and positions the company favorably in upcoming National Essential Medicines List revision cycles.

Market at a Glance

Leading Market Participants

• Pfizer Inc.
• Alnylam Pharmaceuticals
• Ionis Pharmaceuticals
• Intellia Therapeutics
• AstraZeneca India
• Sun Pharmaceutical Industries
• Cipla Limited
• Dr. Reddy's Laboratories
• Biocon Biologics
• Lupin Limited

Regulatory and Policy Environment

The Central Drugs Standard Control Organisation (CDSCO) governs drug approvals for ATTR therapeutics in India under the New Drugs and Clinical Trials Rules 2019, which require local bridging clinical trial data or a waiver for drugs approved in ICH-member jurisdictions. Tafamidis received CDSCO approval in 2020, and vutrisiran completed its Indian registration process in 2023, both benefiting from the accelerated approval pathway under Rule 101 for unmet medical need conditions. The National Policy for Rare Diseases 2021, administered through the Ministry of Health and Family Welfare, classifies hereditary ATTR under Category 3 rare diseases, entitling patients to one-time financial assistance of up to INR 50 lakh — a threshold insufficient for chronic therapy but meaningful for diagnostic cost subsidization and patient identification programs.

The Drugs (Prices Control) Order 2013 and its subsequent amendments give the NPPA authority to cap prices of drugs listed on the National List of Essential Medicines. ATTR drugs are not currently on the NLEM, but advocacy by patient groups and a 2024 Parliamentary Standing Committee recommendation to include select rare disease therapies in the next NLEM revision cycle creates a material regulatory risk for multinational pricing strategies by 2027. Companies must engage proactively with the Indian Council of Medical Research and the Department of Pharmaceuticals to shape the pharmacoeconomic framework that will govern ATTR reimbursement decisions, as the institutional infrastructure for health technology assessment in India remains nascent but is rapidly formalizing under the HTAIn body established in 2017.

Competitive Outlook for India Transthyretin Amyloidosis

By 2032, India's ATTR competitive structure will shift from a multinational duopoly toward a four-to-five player field as Ionis Pharmaceuticals' eplontersen and Intellia's NTLA-2001 complete clinical development and seek Indian registration. Pfizer will retain dominance in ATTR-CM given its established cardiology relationships and first-mover tafamidis franchise, but its share of the polyneuropathy segment will compress as RNA interference and gene-editing therapies demonstrate superior durability data. Domestic manufacturers are unlikely to become primary ATTR drug developers within the forecast period, but Dr. Reddy's and Cipla will aggressively pursue generic tafamidis positioning as soon as patent cliffs materialize, fundamentally altering the pricing floor for the stabilizer segment.

The competitive differentiator by 2030 will not be molecule efficacy — all approved agents demonstrate meaningful clinical benefit — but rather which company builds the deepest diagnostic and patient support ecosystem across India's tier-1 and tier-2 hospital networks. Companies that invest now in TTR genotyping partnerships, cardiologist education programs, and government reimbursement advocacy will translate those investments into patient registry lock-in that persists beyond product-level competition. The market will also see increased participation from diagnostic companies such as Strand Life Sciences and MedGenome, whose TTR genetic testing capabilities represent an upstream competitive node that pharmaceutical players must either partner with or risk ceding patient identification to independently operating entities.